Hyperalgesia – Pipeline Review, 2019

Hyperalgesia refers to a medical condition where the individual develops an increased sensitivity to pain. Conditions and stimuli which do not normally cause hurt in individuals without the condition lead to significant pain in individuals with hyperalgesia. There are different types of hyperalgesia such as primary, secondary and opioid-induced hyperalgesia (OIH). Hyperalgesia is considered a form of neuropathic pain, where the pain results from the damage to the nervous system. A number of potential causes can lead to the development of hyperalgesia but the condition is thought to be a result of changes to nerve pathways.

Current treatment of hyperalgesia includes the use of pain medications for the treatment of neuropathic pain. Drugs like selective serotonin reuptake inhibitors (SSRI) and nonsteroidal anti-inflammatory drugs (NSAIDs) are being used for the treatment of hyperalgesia. For the individuals suffering from opioid-induced hyperalgesia (OIH), the doctor may reduce the dosage of the individual’s opioid medications. Initially, the individual suffers from heightened pain after the reduction of dosage, but the pain eventually subsides and leads the way towards better pain management.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for Hyperalgesia. For instance; ABX-1431, which is being studied by Abide Therapeutics, Inc., is currently in phase-1 clinical trials for an fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and its Neural Correlates.

At present, around 63% of the pipeline candidates for Hyperalgesia are in the phase-2 and phase-4 stages combined. A minority of these studies are being sponsored by the industry.

Report Description

The report on ‘Hyperalgesia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Hyperalgesia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Hyperalgesia.

The report on ‘Hyperalgesia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Hyperalgesia
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Hyperalgesia
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary